Editorial: Novel chimeric antigen receptor (CAR) designs in engineering NK cells for cancer

Chimeric antigen receptor (CAR)-based immunotherapy has revolutionized cancer treatment, particular in hematological malignancies such as B cell acute lymphoblastic leukemic and multiple myeloma. Despite highly effective in hematologic malignancies, conventional CAR-T approaches are constrained by unfavorable manufacturing economics, toxicities including cytokine release syndrome and neurotoxicity, limited durable response and modest efficacy in solid tumors. Natural killer (NK) cells, innate cytotoxic lymphocytes capable of killing transformed without prior sensitization and major histocompatibility complex restriction, have emerged as a compelling alternative for CAR engineering. CAR-NK cells promise off-the-shelf availability, lowered toxicity, and intrinsic anti-tumor functions, yet they also present unique Collectively, it is emphasized that cytokine support, whether through engineered expression (e.g., IL-15), combined cytokine cocktails, or synthetic biology circuits, can amplify NK persistence and function, but must be balanced with safety controls. These insights will be critically important as the field moves toward clinically deployable armored CAR-NK designs.Despite advances in the field, solid tumors remain a formidable challenge for CAR-based By integrating nanomaterials with CAR-NK platforms, this approach may enhance trafficking, persistence, and local activation. Together, these contributions underscore that engineering innovation must extend beyond receptor design to encompass manufacturing, delivery, and microenvironment modulation.Collectively, these studies redefine CAR-NK engineering as a distinct discipline within synthetic immunology. Rather than serving as a derivative of CAR-T therapy, CAR-NK research is developing its own conceptual framework rooted in innate immune biology, technological innovation, and translational foresight. As these advances converge, the vision of safe, effective, and widely accessible off-the-shelf cellular immunotherapies for both hematologic and solid malignancies become increasingly attainable.